SUN-254 A Long-Term, Phase IV Study of Omnitrope®, a Recombinant Human Growth Hormone (rhGH), in Short Children Born Small for Gestational Age (SGA)

Background: Children born SGA are predisposed to metabolic abnormalities. While the therapeutic benefit of rhGH therapy in improving height is widely recognised, it can affect carbohydrate metabolism, potentially inducing diabetes. This ongoing, prospective study aims to evaluate the long-term safet...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarz, Hans-Peter, Giemza, Tomasz, Jathanakodi, Shrihari, Zouater, Hichem, Zabransky, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552986/
http://dx.doi.org/10.1210/js.2019-SUN-254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552986/
http://dx.doi.org/10.1210/js.2019-SUN-254

Ejemplares similares